API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

5

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Acrivon Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Details:

Acrivon is currently advancing its lead candidate, ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types.

Lead Product(s): Prexasertib,Gemcitabine

Therapeutic Area: Oncology Product Name: ACR-368

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Jefferies

Deal Size: $99.4 million Upfront Cash: Undisclosed

Deal Type: Public Offering November 15, 2022

ASK
US

Upload
your Marketing & Sales content

Acrivon Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology...

Details:

Proceeds will support the clinical development of advanced Phase 2 lead asset ACR-368, a potent DNA Damage Response (DDR) inhibitor clinically validated in solid cancers, and in-house drug pipeline driven by the company’s proprietary platform technology.

Lead Product(s): Prexasertib

Therapeutic Area: Oncology Product Name: ACR-368

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Wellington Management Company

Deal Size: $100.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing November 11, 2021

ASK
US

Upload
your Marketing & Sales content

Acrivon Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Acrivon Therapeutics Launches to Advance Clinical Oncology Pipeline Leveraging its Groundbreaking Precision Proteomics Platform

Details:

Acrivon intends to develop prexasertib (also called ACR-368) in accelerated clinical trials treating patients whose tumors are driven by, and depend on, dysregulated CHK1 and CHK2 using the OncoSignature® test.

Lead Product(s): Prexasertib

Therapeutic Area: Oncology Product Name: ACR-368

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2021

ASK
US

Upload
your Marketing & Sales content